<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064348</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-3652</org_study_id>
    <secondary_id>2012-005073-31</secondary_id>
    <secondary_id>U1111-1136-6455</secondary_id>
    <nct_id>NCT02064348</nct_id>
  </id_info>
  <brief_title>A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects</brief_title>
  <official_title>A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to evaluate the effect of
      semaglutide on cardiac repolarisation in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2014</start_date>
  <completion_date type="Actual">April 23, 2015</completion_date>
  <primary_completion_date type="Actual">April 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points</measure>
    <time_frame>0-48 hours after the fourth dose of semaglutide/semaglutide placebo at the 1.5 mg dose level</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcI, based on ECG (electrocardiogram) recordings obtained at 2 out of 8 time points</measure>
    <time_frame>0-24 hours after a single dose of moxifloxacin/moxifloxacin placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1: semaglutide + moxifloxacin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Semaglutide placebo + moxifloxacin/moxifloxacin placebo:
Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide placebo + moxifloxacin placebo/moxifloxacin:
Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.</description>
    <arm_group_label>Arm 1: semaglutide + moxifloxacin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Solution for s.c. injection or tablets for oral administration</description>
    <arm_group_label>Arm 1: semaglutide + moxifloxacin placebo</arm_group_label>
    <arm_group_label>Arm 2A:</arm_group_label>
    <arm_group_label>Arm 2B:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Arm 2A:</arm_group_label>
    <arm_group_label>Arm 2B:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI (Body Mass Index): 20-30 kg/m^2

          -  Body weight: 60-110 kg

          -  Normal ECG (electrocardiogram)

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using an adequate contraceptive method. Women of
             child-bearing potential must use an effective method of birth control for the duration
             of the trial and for 5 weeks following the last dose of semaglutide. Only highly
             effective methods of birth control are accepted (i.e. one that results in less than 1%
             per year failure rate when used consistently and correctly such as implants,
             injectables, combined oral contraceptives, some intrauterine devices), or sexual
             abstinence or vasectomised partner

          -  Any clinically significant disease history, in the opinion of the investigator, or
             systemic or organ

          -  History of seizures, epilepsy, syncope, cardiac arrest, cardiac arrhythmia or Torsades
             de Pointes, A-V (Atrioventricular) block or structural heart disease

          -  Family history of long QT (Interval in the ECG: from the start of the QRS complex to
             the end) syndrome (either objectively diagnosed or suggested by sudden death due to
             cardiac causes before the age of 50 of a 1st degree relative)

          -  Family history of sudden cardiac death before the age of 50 of a 1st degree relative

          -  Use of prescription or non-prescription systemic or topical medicinal products (except
             routine vitamins, acetylsalicylic acid, paracetamol and contraceptives) within 3 weeks
             (or within 5 halflives of the medicinal product, whichever is longest) prior to the
             first dosing of semaglutide

          -  Smoking, drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Demmel V, Sandberg-Schaal A, Jacobsen JB, Golor G, Pettersson J, Flint A. No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects. Diabetes Ther. 2018 Aug;9(4):1441-1456. doi: 10.1007/s13300-018-0442-0. Epub 2018 May 24.</citation>
    <PMID>29799100</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

